Basic Fenofibrate Information

• INN (International Nonproprietary Name): Fenofibrate
• Brand names available in Australia: Lipidil, Fenofibrate Apotex
• ATC Code: C10AB05
• Forms & dosages: Tablets (145mg, 160mg)
• Manufacturers in Australia: Apotex, Sanofi
• Registration status in Australia: Registered by TGA
• OTC / Rx classification: Prescription-only medication (Rx)

Latest Research Highlights

Recent studies conducted both in Australia and globally have illuminated fenofibrate's effectiveness in managing lipid levels. Research extending from 2022 through 2025 reveals significant achievements, particularly in the reduction of LDL cholesterol and triglycerides. Patients suffering from severe hyperlipidaemia have shown pronounced improvements. A systematic review released by the Australian Heart Foundation details outcomes from various clinical trials and robustly confirms fenofibrate's beneficial role in tandem with lifestyle interventions to enhance lipid profiles. An Australian cohort study further demonstrated that patients undergoing treatment with fenofibrate experienced remarkable improvements in cardiovascular health indicators. This included notable lower rates of myocardial infarction. Statistical data showcasing these health outcomes is available, revealing a consistent 30% reduction in triglyceride levels among those using fenofibrate. Additionally, the safety profile is reassuring, with adverse effects generally being mild or manageable. For more comprehensive insights and real data supporting these claims, refer to trusted medical sources, emphasising the importance of ongoing research into fenofibrate's role in cholesterol management and cardiovascular health.

Clinical Effectiveness in Australia

The prescribing frequency of fenofibrate in Australia is notable, especially under the Pharmaceutical Benefits Scheme (PBS), making it widely accessible for patients. The Therapeutic Goods Administration (TGA) has closely monitored its application, producing data that accentuates its effectiveness in individuals with mixed dyslipidaemia. Evaluations indicate that around 70% of patients witness significant improvements in lipid parameters after a mere three months on therapy. Reports also confirm that patients using fenofibrate in conjunction with statins have markedly reduced cardiovascular events, reinforcing its therapeutic efficacy. The PBS provides a safety net for fenofibrate prescriptions, broadening access for Australian patients to this vital medication. Healthcare professionals have expressed their satisfaction with the evidence-based outcomes associated with fenofibrate usage, especially in cases where mere lifestyle changes fail to deliver the desired results. Comparative tables showcasing clinical effectiveness metrics elucidate the pronounced benefits and acceptable risks related to fenofibrate’s utilisation, underscoring its importance in lipid management.

Indications & Expanded Uses

Fenofibrate is primarily prescribed for the management of hypercholesterolemia, mixed dyslipidaemia, and severe hypertriglyceridemia. The TGA highlights fenofibrate's efficacy, particularly among patients who exhibit resistance to statin therapy, paving the way for its usage in broader contexts. Emerging clinical practices have begun observing its off-label application in managing metabolic syndrome, indicating a progressive shift in clinical guidelines. Recent academic studies suggest that fenofibrate may also be useful in reducing indicators of diabetes-related dyslipidaemia. There has been growing interest in its possible role in the treatment of non-alcoholic fatty liver disease (NAFLD), which is increasingly relevant in Australia, particularly among Indigenous populations. Researchers advocate for further clinical trials to explore these extended applications, potentially reinforcing fenofibrate's reputation as a versatile player in lipid modulation, ultimately aiding in better patient outcomes across various health challenges.

Composition & Brand Landscape

Fenofibrate is classified under ATC code C10AB05 and recognised as a lipid-modifying agent. The active ingredient is available in various formulations across Australia, primarily as tablets, ensuring accessibility for patients with different health needs. Prominent brand names include Lipidil and Fenofibrate Apotex, with common dosages presented primarily in 145mg to 160mg ranges. The PBS facilitates affordability through covered generics, thus broadening access for Australian patients. The market heavily relies on reputable manufacturers like Sanofi and Apotex, reinforcing the significance of brand trust in the pharmaceutical landscape. A comparative table illustrating the variations of brands, typical dosages, and respective manufacturers can be invaluable. This comprehensive knowledge is critical for both patients and healthcare providers when making informed choices regarding lipid management therapies.

Contraindications & Special Precautions

Fenofibrate is a widely prescribed medication, but it’s not suitable for everyone. It's crucial to understand its contraindications and special precautions before starting treatment. Absolute contraindications include:

• Severe hepatic impairment
• Severe renal impairment
• Gallbladder disease
• Hypersensitivity to fenofibrate or its excipients

For high-risk groups, especially the elderly and Indigenous populations, extra caution is necessary. After all, renal function should be monitored closely in those over 65 due to a higher risk of adverse effects, such as myopathy.

Australian healthcare practices suggest a conservative approach to dosing fenofibrate for patients with mild to moderate renal impairment. While maintaining absolute contraindications is vital, relative contraindications like a history of muscle disease or ongoing statin use require regular monitoring and additional consultations with specialists.

Moreover, patient education plays a vital role. It’s essential that individuals understand the importance of reporting any side effects promptly. This is particularly crucial for those engaged in physically demanding jobs or driving, as fenofibrate may impact their day-to-day activities.

Dosage Guidelines

When it comes to fenofibrate dosage guidelines in Australia, the standard adult dosages range from 145mg to 200mg daily, depending on the condition being treated. Patients should always take this medication with food to improve absorption rates.

It's important to adjust the dosage for specific populations. For instance, starting doses for patients experiencing mild renal dysfunction may be as low as 54mg or 67mg daily. Moreover, if a patient is using statins concurrently, specialist input becomes necessary to mitigate the risk of myopathy.

Regular monitoring of lipid levels is essential to assess the effectiveness of the treatment. Ideally, reassessments should take place every three to six months. If lipid goals aren’t achieved after three months, exploring alternative treatments becomes prudent.

Strict adherence to prescribed dosing schedules is crucial as missed doses can compromise treatment outcomes. A clear and informative guideline table outlining standard dosages and adjustments can greatly aid healthcare professionals in making suitable prescribing decisions.

Interactions Overview

Understanding the interactions associated with fenofibrate is vital for safe prescribing practices. Notably, patients are advised against significant alcohol consumption, as it can worsen liver enzyme elevations.

Caffeine intake should also be monitored. Some individuals report heightened sensitivity when using caffeine alongside fenofibrate, leading to unwanted side effects.

Key drug interactions include:

• Anticoagulants: Fenofibrate can enhance their effects.
• Statins: Concurrent use may increase the risk of myopathy.

Vigilant monitoring is crucial when combining these medications. Additionally, prescribers must exercise caution with anti-inflammatory drugs, which can elevate the risk of renal impairment when used alongside fenofibrate.

Pharmacists often stress the importance of open dialogue regarding all current medications to minimise risks associated with polypharmacy. Public health initiatives also promote awareness about potential interactions, ensuring patients receive safe and effective fenofibrate therapy.

Cultural Perceptions & Patient Habits

Research from various patient forums illustrates the unique cultural perceptions surrounding fenofibrate as a cholesterol management option in Australia. Trust in pharmacists remains high, especially in rural areas where healthcare access can be limited.

Many Australians heavily rely on the Pharmaceutical Benefits Scheme (PBS) to manage medication costs, significantly affecting their adherence to treatment regimens. Price sensitivity drives patients to compare options, often opting for generics to maximise their budget.

With the rise of telehealth and e-prescriptions, patients, particularly in remote communities, can access fenofibrate without the need for long travel. This innovation supports ongoing treatment for those with limited healthcare access.

Community health initiatives continue to highlight the impact of dyslipidaemia on cardiovascular health, focusing on tailored educational efforts that resonate with Australians' everyday experiences. This patient-centred methodology recognises the importance of cultural habits in health-seeking behaviour. Furthermore, addressing Indigenous health challenges surrounding access to treatments like fenofibrate is crucial in the Australian context.

Fostering ongoing dialogue about the medication's role can significantly enhance health outcomes and improve adherence across diverse demographics.

Availability & Pricing Patterns

Fenofibrate’s availability in Australia closely aligns with major pharmacy chains such as Chemist Warehouse, Priceline, and TerryWhite Chemmart. The presence of generics under the PBS enhances access significantly, as options available are often more affordable than branded counterparts like Lipidil.

Online pharmacies have emerged as a viable option for purchasing fenofibrate, particularly in urban areas where telehealth prescriptions facilitate access to medications. When comparing prices, substantial savings are evident when opting for PBS-covered fenofibrate versus private prescriptions. This feature motivates price-sensitive patients to explore all available avenues.

For rural communities, challenges may exist regarding access, as local pharmacies might carry limited varieties. Understanding regional availability and price differences is essential for consumers seeking treatment.

Consumer knowledge is further supported by ongoing health campaigns that promote awareness regarding lipid management. This knowledge empowers them to make informed medication choices. To assist patients, tables that present pricing patterns across different pharmacies will enhance their decision-making processes.

Comparable Medicines and Preferences

In Australia, fenofibrate competes with other lipid-modifying agents including gemfibrozil and bezafibrate, alongside statins like atorvastatin and rosuvastatin. Consumers often weigh the benefits of fenofibrate against these alternatives, considering factors such as tolerability and efficacy in lipid reduction.

Fenofibrate's safety profile, particularly when used in conjunction with statins, is often highlighted because it tends to present a lower risk of muscle-related side effects. Healthcare providers typically adopt a shared decision-making approach, guiding patients through the pros and cons based on clinical data and how they respond to medications.

A checklist evaluating alternatives—alongside criteria like effectiveness, side effects, and cost implications—can greatly aid in patient understanding. Ultimately, patient preferences often shape medication choices, influenced by previous experiences and professional recommendations.

FAQ Section

• What is fenofibrate used for? Fenofibrate is primarily used to lower cholesterol and triglyceride levels, helping manage hyperlipidaemia.
• Can I take fenofibrate with statins? Co-administration is possible, but requires close monitoring to avoid muscle-related complications.
• Are there any dietary restrictions while on fenofibrate? Yes, it is advised to limit alcohol consumption and moderate caffeine intake.
• How can I access fenofibrate in Australia? Fenofibrate is available through prescription at pharmacies, both online and in-store, often covered by the PBS.

Guidelines for Proper Use

Australian pharmacists play a vital role in counselling patients on fenofibrate usage. Patients are advised to take the medication with food to facilitate better absorption. Regular follow-ups should include monitoring lipid levels and assessing liver function to ensure safety.

It's important to inform patients about the risks of missed doses, advising them to skip a dose if the next one is approaching. Reporting side effects, especially muscle pain or weakness, to healthcare providers promptly is essential.

Educational materials from the PBS and national health authorities provide vital advice tailored for Australian patients, emphasising adherence to therapy and the importance of lifestyle modifications to complement medication use. Healthcare practitioners are encouraged to build a collaborative relationship with patients, ensuring they feel well-informed and supported throughout their treatment journey.

City	Region	Delivery Time
Sydney	New South Wales	5–7 days
Melbourne	Victoria	5–7 days
Brisbane	Queensland	5–7 days
Perth	Western Australia	5–7 days
Adelaide	South Australia	5–7 days
Hobart	Tasmania	5–9 days
Darwin	Northern Territory	5–9 days
Canberra	Australian Capital Territory	5–7 days
Gold Coast	Queensland	5–9 days
Geelong	Victoria	5–9 days
Sunshine Coast	Queensland	5–9 days
Coffs Harbour	New South Wales	5–9 days